ASK OUR EXPERT: Strategies for Testing Biopharma Residual Impurities
Join us for our Ask Our Expert series – keep up to date with industry hot topics!
In this article, Ashleigh Wake, Business Development Director at Intertek Pharmaceutical Services, UK, discusses how a strategic plan is a key to eliminating residual impurities.
Maintaining the purity and quality of biopharmaceuticals is a constant industry concern and challenge, and determining residual impurities is essential to quality assurance. In this article, you'll find out what major risk factors need to be considered when developing a strategy for testing residual impurities. In addition, you'll learn about the specific regulatory requirements for developing risk-based strategies for testing residual impurities in biopharmaceuticals – as well as many other questions answered!
Complete the fields below to access the Q&A.
Reading later? Register now, and you can save the download or bookmark for future viewing.
In this article, Ashleigh Wake, Business Development Director at Intertek Pharmaceutical Services, UK, discusses how a strategic plan is a key to eliminating residual impurities.
Maintaining the purity and quality of biopharmaceuticals is a constant industry concern and challenge, and determining residual impurities is essential to quality assurance. In this article, you'll find out what major risk factors need to be considered when developing a strategy for testing residual impurities. In addition, you'll learn about the specific regulatory requirements for developing risk-based strategies for testing residual impurities in biopharmaceuticals – as well as many other questions answered!
Complete the fields below to access the Q&A.
Reading later? Register now, and you can save the download or bookmark for future viewing.